Loading
Life sciences · Journal article
International Journal of Molecular Sciences · September 11, 2026
Well-designed and adequately powered for the question it asks.
This meta-analysis of 19 RCTs demonstrates that Coptidis Rhizoma formulations, primarily used as adjunctive therapy, produce statistically significant improvements in BMI, HbA1c, and LDL-C across a combined cohort of 1718 participants. Mechanistic studies using network pharmacology and molecular docking identified multi-target regulation of inflammatory and insulin signaling pathways as the likely basis for these clinical effects. While the evidence is rigorous at the meta-analytic level, the source acknowledges that large-scale standardized RCTs with long-term safety follow-up are needed before definitive clinical recommendations can be made.
Systematic review and meta-analysis of randomized controlled trials, integrated with network pharmacology and molecular docking analysis. Adults with obesity, diabetes, and dyslipidemia enrolled in randomized controlled trials evaluating Coptidis-containing formulations, primarily as adjunctive therapy.. Intervention: Coptidis Rhizoma-containing formulations. Compared with: Control or standard therapy (specific comparators not detailed in abstract). n = 1,718.
BMI improvement: standardized mean difference (SMD) = −0.72 (95% CI [−1.00, −0.44], p < 0.00001) HbA1c improvement: SMD = −0.77 (95% CI [−1.07, −0.47], p < 0.00001) LDL-C improvement: SMD = −1.10 (95% CI [−1.57, −0.62], p < 0.00001)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians may consider Coptidis Rhizoma as a complementary adjunct to conventional metabolic therapies based on consistent improvements in BMI, glycemic control, and lipid profiles. However, the source explicitly recommends that future large-scale, standardized RCTs with documented long-term safety and optimized dosing regimens are necessary before firm clinical recommendations can be established.
Rigorous meta-analysis of 19 RCTs with 1718 participants showing consistent, statistically significant improvements across three hard clinical endpoints (BMI, HbA1c, LDL-C) with narrow confidence intervals, supported by mechanistic network pharmacology and molecular docking studies.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians may consider Coptidis Rhizoma as a complementary adjunct to conventional metabolic therapies based on consistent improvements in BMI, glycemic control, and lipid profiles. However, the source explicitly recommends that future large-scale, standardized RCTs with documented long-term safety and optimized dosing regimens are necessary before firm clinical recommendations can be established.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Obesity, diabetes, and dyslipidemia form an interconnected metabolic disease cluster driven by insulin resistance and chronic inflammation. This study evaluated the clinical efficacy and multi-target mechanisms of Coptidis Rhizoma for these metabolic disorders through an integrated systematic review, meta-analysis of randomized controlled trials (RCTs), network pharmacology, and molecular docking. Meta-analysis of 19 RCTs (n = 1718) demonstrated that Coptidis-containing formulations, primarily as adjunctive therapy, significantly improved primary clinical endpoints across all three metabolic conditions: body mass index (BMI: SMD = −0.72, 95% CI [−1.00, −0.44], p < 0.00001), glycated hemoglobin (HbA1c: SMD = −0.77, 95% CI [−1.07, −0.47], p < 0.00001), and low-density lipoprotein cholesterol (LDL-C: SMD = −1.10, 95% CI [−1.57, −0.62], p < 0.00001). Network analysis revealed shared targets enriched in lipid metabolism, inflammatory signaling, and PI3K-Akt/MAPK cascades. Molecular docking demonstrated favorable structural compatibility and predicted docking scores (ranging from −7.1 to −9.5 kcal/mol) of berberine toward key hub proteins, including PIK3CA, JAK2, MAOA, and PARP1. Consequently, Coptidis Rhizoma provides tangible clinical benefits across interconnected metabolic outcomes via the multi-target regulation of inflammatory and insulin signaling pathways. Clinically, Coptidis-containing formulations show promise as a complementary adjunct to conventional metabolic therapies, though future large-scale, standardized RCTs remain necessary to confirm long-term safety and optimize dosing regimens.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.